Allelix Clones Receptor For Intestinal Growth Factor GLP-2

Toronto, Canada - February 15, 1999 - Scientists from Allelix Biopharmaceuticals Inc. (TSE/ME: AXB) will report the cloning of the receptor for Glucagon-like Peptide 2 (GLP-2), which plays a unique role in intestinal growth and nutrient absorption, in the February 16 issue of the Proceedings of the National Academy of Sciences. The findings offer valuable information about the specificity and action of GLP-2, for which Allelix has developed a proprietary analog, ALX-0600, as a potential therapy for several gastrointestinal disorders including short bowel syndrome. Because the GLP-2 receptor was found almost exclusively in the small intestine, ALX-0600 is expected to act in a highly specific manner at the target site.

Normally, GLP-2, a peptide hormone, acts in the body as a potent stimulator of cell growth in the lining of the small bowel. This growth dramatically increases the surface area of the intestine, where nutrients are extracted from food and then circulated into the body. Diseases such as short bowel syndrome, in which the decreased surface area results in reduced nutrient absorption, can lead to chronic hospitalizations and even death. No effective treatments are currently available for patients with the most severe form of these diseases.

"The cloning of this naturally occurring receptor is a critical step in determining exactly where and how GLP-2 functions in the body," said first author Donald G. Munroe, Ph.D., senior research scientist at Allelix. "With the cloned human receptor in hand, we are now able to better understand the mechanisms that connect GLP-2 with intestinal growth and nutrient absorption at the cellular and molecular levels."

Allelix has completed work in phase I clinical studies of ALX-0600 for short bowel syndrome, a condition estimated to affect 40,000 to 50,000 sufferers worldwide. Phase II studies are planned for 1999. Allelix is also considering investigational trials for additional clinical indications such

Contact: Ernie Knewitz
212-696-4455 x204
Noonan/Russo Communications

Page: 1 2 3

Related biology news :

1. Allelix drug increases bone density and content in women with osteoporosis
2. Millennium Clones Diet-Induced Obesity Gene
3. International Research Team Clones New Skin Cancer Gene
4. Receptor found that guides nerve cells to their final connecting sites
5. Receptor could be target for cancer therapy
6. Receptor-dependent protein activation without a receptor
7. Researchers Engineer A Way To Improve T-Cell Receptors
8. Studies At Cedars-Sinai Confirm Identity Of An Elusive Receptor In Human Cells -- A Breakthrough In Understanding, Fighting Septic Shock
9. Scientists Discover Function For Type III TGF-Beta Receptor
10. Antiviral From Advanced Viral Research Corp. Inhibits CCR5 Cell Receptor For HIV
11. Scientists Discover Key Cog In Receptor That Governs Ripening

Post Your Comments:

(Date:8/1/2018)... ... August 01, 2018 , ... RURO, Inc., a ... version 7.1. Limfinity® is the software framework that all of RURO’s products are ... both current users and the future of RURO’s laboratory software portfolio. , To ...
(Date:8/1/2018)... ... 2018 , ... Visikol CEO Dr. Michael Johnson has announced that through the ... Visikol will far exceed its original 2018 revenue projections. , Over the last ... pathology tools, whole mount imaging techniques and advanced 3D cell ...
(Date:7/31/2018)... ... July 31, 2018 , ... ... Muzek as Business Development Manager. In this role, Mr. Muzek will lead the ... Lifecycle’s continued growth and expansion. , With over 20 years in business ...
Breaking Biology News(10 mins):
(Date:8/9/2018)... ... August 08, 2018 , ... ActX ... and is continually updated by a talented scientific team that includes geneticists, PharmD’s, ... , 1. Information on the medical impact of a patient’s genetic variants ...
(Date:8/9/2018)... ... August 09, 2018 , ... ... Rockland, and Dr. Birte Aggeler, Director of Antibody Development at Bio-Techne, composed a ... article was published online on August 9, 2018 and will be printed in ...
(Date:8/1/2018)... (PRWEB) , ... August 01, ... ... healer, today announces research results on the significant impact of a proprietary ... responses. , The preclinical research assessed biomarkers for systemic and organ-specific ...
(Date:7/27/2018)... ... July 27, 2018 , ... ... Advocacy Group (BRAG®) and representatives of the Biotechnology Innovation Organization (BIO) met ... recently-issued white paper, “Proposal for a Toxic Substances Control Act (TSCA) Inventory ...
Breaking Biology Technology:
Cached News: